LILAC-TIMI 76 is a randomized, double, blind placebo-controlled phase 3 trial investigating the efficacy and safety of the factor XI inhibitor abelacimab in~1,900 patients with AF deemed unsuitable for anticoagulation therapy.
Drs. Christian Ruff and Robert Giugliano discuss LILAC-TIMI 76
CONTACT US about LILAC